Skip to main content

Table 1 Main characteristic of the included studies

From: Percutaneous nephrolithotomy versus flexible ureteroscopic lithotripsy in the treatment of upper urinary tract stones: a meta-analysis comparing clinical efficacy and safety

Reference, year

Nation

primary site

Study design

Surgical technique

Sample size

Age (year)

Sex

(M/F)

Stone burden

Stone side

Mean ± SD

Median ± range

(Mean ± SD)

Median ± range

(left / right)

Aboutaleb, 2012 [9]

Kuwait

Lower calyx

CS

PCNL

19

45.33 ± 14.30

–

14/5

17.30 ± 3.30

–

ND

fURL

13

47.20 ± 15.20

–

7/6

14.50 ± 3.20

–

ND

Armagan, 2015 [10]

Turkey

Kidney

CS

mPCNL

68

43.60 ± 18.90

–

35/33

13.70 ± 4.20

–

ND

fURL

59

49.30 ± 15.30

–

36/23

14.40 ± 3.10

–

ND

Bozkur, 2011 [11]

Turkey

Lower calyx

CS

PCNL

42

47.40 ± 15.50

–

25/17

1.70 ± 0.12

–

20/22

fURL

37

41.20 ± 13.60

–

21/16

1.65 ± 0.69

–

19/18

Chung, 2008 [12]

America

Kidney

CS

PCNL

15

–

58.00a

40/60

–

1.80 (1.0–2.0)

60/40

fURL

12

–

58.50a

58/42

–

1.25 (1.0–1.9)

58/42

Ferroud, 2011 [13]

French

Kidney

CS

mPCNL

101

51.70 ± 16.10

–

80/21

8.90 ± 2.70

–

ND

fURL

43

49.20 ± 14.80

–

28/15

8.50 ± 3.20

–

ND

Gu, 2013 [14]

China

Upper ureter

RCT

mPCNL

30

42.50 ± 10.10

–

17/13

17.27a

–

16/14

fURL

29

44.22 ± 13.00

–

18/11

16.23a

–

12/17

Hu, 2016 [15]

China

ureter

CS

mPCNL

104

65.50 ± 4.90

–

56/48

15.80 ± 3.40

–

53/51

fURL

80

65.10 ± 5.20

–

45/35

15.80 ± 3.40

–

47/33

Kirac, 2013 [16]

Turkey

Lower calyx

CS

mPCNL

37

41.02 ± 10.30

–

25/12

10.50 ± 2.20

–

16/22

fURL

36

37.80 ± 8.70

–

22/14

10.20 ± 2.90

–

14/22

Kruck, 2013 [17]

Germany

Kidney

CS

mPCNL

172

53.30 ± 14.80

–

109/63

12.60 ± 9.50

–

ND

fURL

108

50.00 ± 16.70

–

69/39

6.80 ± 6.90

–

ND

Kumar, 2015 [18]

India

Lower calyx

RCT

mPCNL

41

33.70 ± 1.60

–

20/21

13.30a

–

22/19

fURL

43

33.40 ± 1.40

–

20/23

13.10a

–

22/21

Lee, 2015 [6]

Korea

Kidney

RCT

mPCNL

35

59.30 ± 13.30

–

28/7

39.10a

–

21/14

fURL

33

55.80 ± 11.20

–

28/5

28.90a

–

23/10

Ozgor, 2016 [19]

Turkey

Kidney

CS

mPCNL

56

51.40 ± 14.30

–

25/31

19.50 ± 3.90

–

25/31

fURL

56

54.20 ± 10.60

–

22/34

18.30 ± 3.20

–

37/19

Ozgor, 2018 [20]

Turkey

Kidney

CS

mPCNL

58

66.90 ± 5.90

–

28/30

20.30 ± 5.60

–

ND

fURL

60

67.70 ± 6.70

–

33/27

19.00 ± 4.50

–

ND

Pan, 2013 [21]

China

Kidney

CS

mPCNL

59

49.37 ± 14.20

–

36/20

22.37 ± 2.70

–

23/36

fURL

56

49.32 ± 13.70

–

37/22

22.28 ± 2.60

–

30/26

Sabnis, 2012 [22]

India

Kidney

CS

mPCNL

32

44.48 ± 12.36

–

19/13

1.52 ± 0.33

–

10/22

fURL

32

49.28 ± 12.19

–

25/7

1.42 ± 0.34

–

16/16

Sabnis, 2013 [23]

India

Kidney

RCT

mPCNL

35

38.60 ± 14.60

–

22/13

11.00a

–

16/19

fURL

35

43.70 ± 12.10

–

24/11

10.40a

–

18/17

Schoenthaler,2015 [24]

Germany

Kidney

CS

UMP

30

–

54.30 (19–72)

17/13

–

15.10 (10–20)

ND

fURL

30

–

56.30 (18–76)

ND

–

14.40 (10–20)

ND

Wilhelm, 2015 [25]

Germany

Kidney

CS

UMP

25

–

51.56 (15–75)

15/10

–

19.28 (10–35)

ND

fURL

25

–

51.36 (19–77)

19/6

–

19.20 (10–35)

ND

Zhang, 2014 [26]

China

Upper ureter

CS

mPCNL

32

42.70 ± 13.60

–

24/8

15.60 ± 2.50

–

ND

fURL

44

43.30 ± 11.00

–

29/15

14.90 ± 2.30

–

ND

  1. RCT randomized controlled trial, CS cohort study, PCNL percutaneous nephrolithotomy, mPCNL minipercutaneous nephrolithotomy, fURL flexible ureteroscopic lithotripsy, ND not demonstrated
  2. aNo SD or range was demonstrated in primary studies
Back to article page

BMC Urology

ISSN: 1471-2490

Contact us